RxDoctor Payments Data

Deborah McDowell

Nurse Practitioner · Bakersfield, CANPI 1841262326

Payments from drug & device makers

$833in general payments, 2019–2025

Across 19 payments — averaging $43.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$462
  • Novo Nordisk$125
  • Abbott$114
  • AstraZeneca$33
  • AbbVie$27
  • Verrica Pharmaceuticals Inc.$20
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$833 in reported general payments places this provider in the 75th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$147,847
Medicare patients
311
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$50,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$48,602
OzempicSemaglutide38$35,524
EliquisApixaban36$29,563
JardianceEmpagliflozin25$20,696
TrulicityDulaglutide16$16,797
JanuviaSitagliptin Phosphate18$16,653
XareltoRivaroxaban16$13,517
FarxigaDapagliflozin Propanediol14$7,765
Breo ElliptaFluticasone/Vilanterol14$6,331
Levothyroxine Sodium304$4,882
Dexlansoprazole DrDexlansoprazole18$4,306
Irbesartan162$3,802
EdarbiAzilsartan Medoxomil11$3,677
Midodrine Hcl19$3,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$462$54,93374 claims
Novo NordiskOzempic$125$35,52438 claims
AstraZenecaFarxiga$33$7,76514 claims
AbbVieSynthroid$27$1,64835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →